Matthew J Stotts1, Opaku Adjapong2, David E Kaplan1,2. Show Affiliations » 1. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA.
Abstract
Entities: Disease
Mesh： See more » AgedAntineoplastic Agents, Immunological/adverse effectsAntineoplastic Agents, Immunological/therapeutic useBiopsy, NeedleCarcinoma, Hepatocellular/drug therapyCarcinoma, Hepatocellular/pathologyCarcinoma, Hepatocellular/surgeryDrug Eruptions/etiologyDrug Eruptions/therapyDrug Substitution/methodsFollow-Up StudiesHepatectomy/methodsHumansImmunohistochemistryLiver Neoplasms/drug therapyLiver Neoplasms/pathologyLiver Neoplasms/surgeryMaleNeoplasm Invasiveness/pathologyNeoplasm StagingNivolumab/adverse effectsNivolumab/therapeutic usePhenylurea Compounds/therapeutic usePhototherapy/methodsPrednisone/therapeutic useQuinolines/therapeutic useTreatment OutcomeWithholding Treatment
Substances： See more » Antineoplastic Agents, ImmunologicalPhenylurea CompoundsQuinolinesNivolumablenvatinibPrednisone
Year: 2019 PMID： 31004512 DOI： 10.1002/hep.30659
Source DB: PubMed Journal: Hepatology ISSN： 0270-9139 Impact factor: 17.425